← All trials
NCT04123561
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2019
- Primary completion
- Aug 23, 2021
- Completion date
- Aug 23, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 500
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Taiwan Liposome CompanyLead sponsor
- Taiwan Liposome CompanyStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.